Which funds bought or sold TEVA in Q3 2026?
Teva Pharmaceutical Inds Ltd. 13 funds bought, 1 sold, out of 109 tracked funds that have filed for Q3 2026. Among active managers, the estimated net flow was +$855M.
Holdings as of Sep 30, 2026 (Q3 2026)13F deadline Nov 16, 2026 (45 days after quarter end)
- BlackRockNEW+$2.5B
- Vanguard Capital+$1.3B
- GeodeNEW+$470M
- GlenviewNEW+$300M
- Capital World+$217M
- Arrowstreet+$188M
- SusquehannaNEW+$117M
- Marshall WaceNEW+$110M
- Legal & General+$95M
- CPP Investments+$84M
- Northern Trust−$81M
Top 10 each side. NEW = opened a position, OUT = sold the whole position.
Bought (13)
| Fund | Change | Est. $ | Now |
|---|---|---|---|
| BlackRock Index giant | New | +$2.5B | $2.5B |
| Vanguard Capital Index giant | Added+1225060.2% | +$1.3B | $1.3B |
| Geode Index giant | New | +$470M | $470M |
| Glenview Hedge fund | New | +$300M | $300M |
| Capital World Asset manager | Added+43.6% | +$217M | $713M |
| Arrowstreet Quant & multi-strategy | Added+902.9% | +$188M | $209M |
| Susquehanna Quant & multi-strategy | New | +$117M | $117M |
| Marshall Wace Quant & multi-strategy | New | +$110M | $110M |
| Legal & General Asset manager | Added+60.8% | +$95M | $250M |
| CPP Investments Sovereign & pension | Added+135.1% | +$84M | $146M |
| DME / Greenlight Value investor | New | +$72M | $72M |
| Adage Hedge fund | Added+74.1% | +$69M | $163M |
| GQG Growth / crossover | New | +$19M | $19M |
Sold (1)
| Fund | Change | Est. $ | Now |
|---|---|---|---|
| Northern Trust Bank & broker | Trimmed-25.6% | −$81M | $234M |
Source: SEC EDGAR Form 13F-HR for each fund, holdings as of Sep 30, 2026. Shares only (options excluded). Estimated $ = change in shares × quarter-end price. Funds may have traded since. Methodology. Not investment advice.